Hence, the combination of pembrolizumab with platinum-based chemotherapy in advanced squamous NSCLC and nonsquamous NSCLC has been considered beneficial, regardless of the PD-L1 TPS [44,45]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.